Subtype
Lung Non-Squamous Non-Small Cell Carcinoma
CI-CAN-00005826Explore in graph →
93 active trials5 approved drugs127 evidence items
- NCIt
- C135017
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005826Explore in graph →
Clinical trials
408 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (56)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02093000 | A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma | completed | — | 201 | Hoffmann-La RocheINDUSTRY | 1 | Feb 23, 2018 | clinicaltrials |
| NCT01378962 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER) | completed | Phase 2 | 50 | Hoffmann-La RocheINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02326285 | Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB(NeoIntercal) | terminated | Phase 2 / Phase 3 | 1 | AIO-Studien-gGmbHOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03127319 | A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases | unknown | Phase 2 | 40 | Affiliated Hospital of Hebei UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT03351842 | Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% | recruiting | Phase 2 | 460 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT03376191 | Apatinib in Advanced Non-squamous，NSCLC | unknown | — | 100 | Jian FangOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 18, 2017 | clinicaltrials |
| NCT01995188 | A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 1 | Oct 4, 2017 | clinicaltrials |
| NCT01351415 | A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 485 | Hoffmann-La RocheINDUSTRY | 18 | Sep 18, 2017 | clinicaltrials |
| NCT01723878 | ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations | completed | — | 144 | Hoffmann-La RocheINDUSTRY | 1 | Sep 11, 2017 | clinicaltrials |
| NCT02121925 | Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up(ONC003) | terminated | — | 227 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02715102 | Circulating Tumor DNA in Patients at High Risk for Lung Cancer | terminated | — | 39 | Pathway GenomicsINDUSTRY | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01827852 | AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung | completed | — | 1,107 | Hoffmann-La RocheINDUSTRY | 1 | Jul 28, 2017 | clinicaltrials |
| NCT00942825 | Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)(CBP08-02) | completed | Phase 2 | 195 | CanBas Co. Ltd.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT01836133 | An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)(ELEMENT) | completed | — | 70 | Hoffmann-La RocheINDUSTRY | 1 | May 4, 2017 | clinicaltrials |
| NCT02679443 | Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy(PEMVITASTART) | completed | N/A | 161 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01160601 | Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer | completed | Phase 2 | 86 | Peregrine PharmaceuticalsINDUSTRY | 5 | Apr 19, 2017 | clinicaltrials |
| NCT01726296 | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care | completed | N/A | 1,440 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2017 | clinicaltrials |
| NCT02087241 | Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer | terminated | Phase 2 | 22 | AstraZenecaINDUSTRY | 1 | Mar 29, 2017 | clinicaltrials |
| NCT03090815 | Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma | unknown | — | 100 | The University of Hong KongOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT02282267 | Blood Detection of EGFR Mutation For Iressa Treatment(Benefit) | unknown | N/A | 188 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02787447 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | unknown | Phase 2 | 46 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT00642824 | A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | terminated | Phase 2 | 3 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00776698 | A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 1 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00806923 | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 1,044 | Hoffmann-La RocheINDUSTRY | 20 | Nov 2, 2016 | clinicaltrials |
| NCT00975182 | A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors | completed | Phase 1 | 58 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01070927 | An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer | completed | Phase 2 | 7 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01194050 | An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer | completed | — | 289 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01333007 | An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | completed | — | 423 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01343914 | An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy | completed | — | 118 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01488331 | An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer | completed | — | 217 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01659970 | PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | completed | — | 152 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01790217 | An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC) | completed | — | 52 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02951897 | Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma(CTCs detection) | unknown | N/A | 120 | Third Military Medical UniversityOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02951637 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT02946216 | ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC | unknown | — | 200 | First People's Hospital of HangzhouOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT01496742 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 259 | Genentech, Inc.INDUSTRY | 13 | Sep 23, 2016 | clinicaltrials |
| NCT01990261 | A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment(STAR) | terminated | — | 33 | Hoffmann-La RocheINDUSTRY | 1 | Sep 16, 2016 | clinicaltrials |
| NCT02898857 | Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma(NOTCH) | unknown | — | 18 | University Hospital, MontpellierOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT01519804 | A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 108 | Genentech, Inc.INDUSTRY | 9 | Sep 2, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Feb 23, 2018source: clinicaltrials